Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers

HT-KIT dramatically suppresses tumor growth in preclinical models of GIST and systemic mastocytosis. Treatment shows potent downregulation of oncogenic KIT mutations with no observed systemic toxicity. IND filing expected early 2026, opening pathway to first-in-human trials. Preclinical…